Health Economics›Light-chain (AL) amyloidosis›First-line therapy (including transplant ineligible)

First-line therapy (including transplant ineligible)

Light-chain (AL) amyloidosis · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
CTD Variant #02	—	R 42 203	28d	—	—	—	—	—
VDC Variant #04	—	R 10 611	35d	~30.0 mo	—	~27	~R 286 501 PFS proxy · indirect	1
VMD Variant #17	—	R 9 406	35d	—	—	—	—	1
Bortezomib and Dexamethasone (Vd) Variant #01	—	R 8 080	28d	~9.4 mo	~38.7 mo	~11	~R 88 876 PFS proxy · indirect	10
Lenalidomide monotherapy N/A - secondary systemic drug	—	R 6 361	90d	~41.0 mo	~113.8 mo	~14	~R 89 057 PFS proxy · indirect	5
Doxycycline-CyBorD Variant #01	—	R 4 939	28d	—	—	—	—	—
Dara-CyBorD Variant #01 Partial	—	R 4 903	28d	—	—	—	—	—
CRd Variant #07	—	R 4 002	28d	—	—	—	—	—
MRD Variant #01	—	R 2 410	28d	—	—	—	—	—
Melphalan and Dexamethasone Variant #05	—	R 1 487	42d	—	45.5 mo	—	—	2
Melphalan and Prednisone (MP) Variant #18	—	R 206	42d	—	~29.1 mo	—	—	2
Colchicine monotherapy Variant #01	—	R 202	28d	—	—	—	—	—
Placebo Partial	—	—	—	~22.2 mo	—	—	—	2
No induction Partial	—	—	—	—	~31.7 mo	—	—	5

14 of 14 regimens shown